Results 321 to 330 of about 327,068 (394)

A Case of Cryobiopsy of a Large Allergic Bronchopulmonary Aspergillosis‐Associated Mucus Plug

Respirology Case Reports, Volume 13, Issue 6, June 2025.
We report a rare case of an allergic bronchopulmonary aspergillosis‐associated large mucus plug that was removed by cryobiopsy. When grasped during forceps biopsy, mucus plugs, which are soft tissue, can collapse, making them difficult to remove. Cryobiopsy is a more suitable way to remove mucus plugs because it freezes the plugs, allowing them to be ...
Yusuke Nakamura, Yuto Goto, Nobuhiko Tsukada, Azusa Tsukada, Nobuhiko Uchida, Nana Yazawa, Yasuo Shimizu, Seiji Niho   +7 more
wiley   +1 more source

Conceptual GeoHealth Framework for Disaster Response Research: Case Study for Wildland Urban Interface (WUI) Fires and Data Integration

GeoHealth, Volume 9, Issue 6, June 2025.
Abstract With climate change contributing to an increase in frequency and severity of extreme weather events like wildfires, droughts, and hurricanes, there is a growing need for coordinated research efforts to understand the impact of these events on human health.
J. Barkoski, A. Liu, E. Van Fleet, S. Ramsey, A. Miller   +4 more
wiley   +1 more source

Sinonasal Outcomes Obtained after 2 Years of Treatment with Benralizumab in Patients with Severe Eosinophilic Asthma and CRSwNP: A "Real-Life" Observational Study. [PDF]

J Pers Med
De Corso E, Mele DA, Rizzi A, Spanu C, Corbò M, Pisciottano S, Mastrapasqua RF, Baroni S, Porru DP, De Maio G, Rizzuti A, Di Bella GA, Ortolan A, Bonini M, Cefaloni F, Boccabella C, Lombardi F, Chini R, Caruso C, Panfili M, Galli J.   +20 more
europepmc   +1 more source

Systemic EP4 receptor agonist and Arginase‐1 therapy in a murine model of chronic asthma and influenza virus‐induced asthma exacerbation

British Journal of Pharmacology, Volume 182, Issue 12, Page 2803-2820, June 2025.
Background and Purpose Myeloid‐derived suppressor cells (MDSCs) play important roles in the pathogenesis of asthma. Recent studies demonstrate that their function can be modulated by different pharmacological approaches. In this study, we focussed on the effects of systemically administered prostaglandin EP4 receptor agonist L‐902,688 and pegylated ...
Tim Lange, Tobias Brunn, Charlotte Vetter, Konstantin Bloch, Nora Vedder, Chiel van Geffen, Philipp Gercke, Saeed Kolahian   +7 more
wiley   +1 more source

Long-term effects of mepolizumab in patients with severe eosinophilic asthma: a 6-year real-life experience. [PDF]

Front Pharmacol
Stanziola AA, Candia C, Nazzaro G, Caso A, Merola C, Gallotti L, Maniscalco M.   +6 more
europepmc   +1 more source

Ten‐year follow‐up of a case of eosinophilic granulomatous with polyangiitis

ESC Heart Failure, Volume 12, Issue 3, Page 2361-2366, June 2025.
Jiange Qiao, Mingjie Cao, Tao Ren, Chen Gong, Zhijun Jie, Qingmin Yang, Jindong Shi   +6 more
wiley   +1 more source

Type 2 Inflammation and Its Role in Dermatologic Diseases

International Journal of Dermatology, Volume 64, Issue 6, Page 978-991, June 2025.
ABSTRACT Atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria are immune‐mediated, inflammatory skin conditions characterized by intense itch and disease‐specific skin lesions. Despite their different clinical presentations, the three diseases are unified by an aberrant type 2 immune response involving type 2 cytokines, immune cells,
Raj Chovatiya, Jason E. Hawkes, Douglas DiRuggiero, Leigh Ann Pansch, Elizabeth Simcox, Tayler Gonzalez   +5 more
wiley   +1 more source

Benralizumab: Effectiveness in Patients with Uncontrolled Severe Eosinophilic Asthma at 6 and 12 Months at a Third-Level Care Hospital. Capacity for ICS-LABA Therapy Reduction. [PDF]

J Asthma Allergy
González-Tuyub YH, González-Iñiguez KD, Lizarazo-Guiza PC, García-García SR.   +3 more
europepmc   +1 more source

Efficacy and safety of tozorakimab in moderate‐to‐severe atopic dermatitis: A Phase 2a randomized controlled trial (FRONTIER‐2)

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 6, Page 1126-1133, June 2025.
In FRONTIER‐2 (NCT04212169), a Phase 2a, randomized, placebo‐controlled study of 148 adults with moderate‐to‐severe atopic dermatitis, no statistically significant differences between tozorakimab and placebo were observed in the percentage change in EASI score from baseline to Week 16.
J. I. Silverberg, M. N. Mustapa, F. Reid, A. Lei, R. Smith, R. Moate, A. Kelly, R. Chen, M. Gavala, E. Jimenez, M. G. Belvisi, M. W. Sadiq, C. Kell, H. C. Pandya   +13 more
wiley   +1 more source

IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma. [PDF]

Mucosal Immunol
Luo J, Chen W, Liu W, Jiang S, Ye Y, Shrimanker R, Hynes G, Klenerman P, Pavord ID, Xue L.   +9 more
europepmc   +1 more source